Home › Companies › CMPS

COMPASS Pathways

CMPS Lead: NDA Submitted 6 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2025-02-15

Pipeline (3 active programs)

psilocybin

COMP360

Small Molecule Target: 5-HT2A receptor

Biotech Distilled coverage (6)

2026-07-07 UPDATE: Compass Pathways (CMPS) - The Last Piece of Clinical Risk Just Got Retired
2026-04-27 UPDATE: Compass Pathways (CMPS) - The Regulatory Anvil Just Got Lifted 🔒 Paid
2026-03-28 UPDATE: Compass Pathways (CMPS) - The Accounting Trap Net Loss and the 7,300-Center Flex 🔒 Paid
2026-02-28 UPDATE: Compass Pathways (CMPS) – The $341 Million Dilution Double-Tap 🔒 Paid
2026-02-21 UPDATE: Compass Pathways (CMPS) – The Coin Lands Heads, and the Bill Comes Due 🔒 Paid
2026-01-15 Compass Pathways (CMPS): Scientific Deep Dive for COMP360 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.